× Industry Reports Services Press Release Contact us About us

Europe Regenerative Medicine Market Forecast 2027 By Type (Cell Therapy, Tissue Engineering, Gene Therapy), By Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology), Research Report, Country Outlook (Germany, UK, France, Italy, Spain, Sweden, The Netherlands, Russia, Denmark, Switzerland, Poland, Belgium, Norway, Finland), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: October 2021 | Publisher: Graphical Research Report ID: GR1981 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.3    References & sources

1.3.1    Secondary

1.3.2    Primary

Chapter 2   Executive Summary

2.1    Europe regenerative Medicine industry summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Type trends

2.1.3    Application trends

Chapter 3   Industry Insights

3.1    Industry segmentation

3.2    Industry outlook, 2016 – 2027 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Growing prevalence of chronic diseases

3.3.1.2    Rising investment in development of innovative medicine

3.3.1.3    High adoption of stem cell technology in disease treatment

3.3.1.4    String product pipelines of potential therapies

3.3.2    Industry pitfalls & challenges

3.3.2.1    Stringent regulatory framework

3.3.2.2    High cost associated with some regenerative medicine therapy

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Europe Regenerative Medicine Market, By Type

4.1    Market trends

4.2    Cell therapy

4.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.3    Tissue engineering

4.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.4    Gene therapy

4.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.5    Others

4.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 5   Europe Regenerative Medicine Market, By Application

5.1    Market trends

5.2    Oncology

5.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.3    Dermatology

5.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.4    Musculoskeletal

5.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.5    Neurology

5.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.6    Cardiovascular

5.6.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.7    Wound healing

5.7.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.8    Ophthalmology

5.8.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.9    Others

5.9.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 6   Europe Regenerative Medicine Market, By Country

6.1    Market trends

6.2    Germany

6.2.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.2.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.3    UK

6.3.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.3.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.4    France

6.4.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.4.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.5    Italy

6.5.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.5.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.6    Spain

6.6.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.6.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.7    Sweden

6.7.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.7.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.8    The Netherlands

6.8.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.8.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.9    Russia

6.9.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.9.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.10    Denmark

6.10.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.10.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.11    Switzerland

6.11.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.11.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.12    Poland

6.12.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.12.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.13    Belgium

6.13.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.13.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.14    Norway

6.14.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.14.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

6.15    Finland

6.15.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

6.15.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

Chapter 7   Company Profiles

7.1    Novartis AG

7.1.1    Business overview

7.1.2    Financial data

7.1.3    Product landscape

7.1.4    Strategic outlook

7.2    Amgen

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.3    Bristol Myers Squibb

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.4    BLUEBIRD BIO

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.5    SPARK THERAPEUTICS

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.6    GlaxoSmithKline Plc.

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.6.5    SWOT analysis

7.7    ORCHARD THERAPEUTICS

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.8    BIOSOLUTIONS

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.9    TERUMO BCT

7.9.1    Business overview

7.9.2    Financial data

7.9.3    Product landscape

7.9.4    Strategic outlook

7.10    AVITA MEDICAL

7.10.1    Business overview

7.10.2    Financial data

7.10.3    Product landscape

7.10.4    Strategic outlook

7.11    Smith and Nephew

7.11.1    Business overview

7.11.2    Financial data

7.11.3    Product landscape

7.11.4    Strategic outlook

7.12    KITE (Gilead Science)

7.12.1    Business overview

7.12.2    Financial data

7.12.3    Product landscape

7.12.4    Strategic outlook
 


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]